ClinicalTrials.gg
CompletedNCT04773600Updated Oct 4, 2024Results posted

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

A Phase 3 interventional study of Roflumilast Cream and Vehicle cream in Atopic Dermatitis Eczema, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 53 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
683
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.

Enrollment
2nd of 13
683 · median 136
Started
2021
with 3 others
Phase 3
6 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
8 of 13
Arcutis Biotherapeutics, Inc.

Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 4th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing roflumilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema). This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 0.15% cream or vehicle is applied once daily (qd) for 4 weeks by participants with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis Eczema
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants legally competent to sign and give and, if appropriate, assent as required by local laws.
  2. Males and females, ages 6 years and older at time of signing Informed Consent (Screening). Only subjects 18 years and older will be enrolled at sites located in the province of Québec in Canada.
  3. Diagnosed with atopic dermatitis 6 months duration (3 months for children), as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening.
  4. Females of (FOCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline/Day 1. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of throughout the trial.
  5. In good health as judged by the Investigator.
  6. Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any serious medical condition or abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
  2. Has unstable AD or any consistent requirement for high potency topical .
  3. Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study.
  4. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  5. Previous treatment with ARQ-151.
  6. Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.
  7. Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
  8. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
683 participants (actual)

Study arms

  • Experimental
    Roflumilast Cream 0.15%

    Participants apply roflumilast cream 0.15% once daily (qd) for 4 weeks.

    Drug: Roflumilast Cream

  • Placebo comparator
    Vehicle Cream

    Participants apply vehicle cream qd for 4 weeks.

    Drug: Vehicle cream

Interventions

  • Roflumilast cream 0.15% for topical application

    Also known as: ARQ-151

  • DrugVehicle cream

    Vehicle cream for topical application

06

What researchers measure

Primary outcomes

  1. Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4

    The percentage of participants achieving viGA-AD "success" is presented with multiple imputation of missing observations. viGA-AD "success" is defined as a viGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.

    Time frame: Week 4

Secondary outcomes

  1. Achievement of vIGA-AD Success at Week 4 in Participants With "Moderate" Baseline Scores

    The percentage of participants with moderate baseline scores achieving viGA-AD "success" is presented with multiple imputation of missing observations. viGA-AD "success" is defined as a viGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from baseline in participants with a 'moderate' baseline viGA-AD score. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.

    Time frame: Week 4

  2. vIGA-AD Success at Week 2

    The percentage of participants achieving viGA-AD "success" is presented with multiple imputation of missing observations. viGA-AD "success" is defined as a viGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.

    Time frame: Week 2

  3. vIGA-AD Success at Week 1

    The percentage of participants achieving viGA-AD "success" is presented with multiple imputation of missing observations. viGA-AD "success" is defined as a viGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.

    Time frame: Week 1

  4. Achievement of a 4-point Reduction at Week 4 in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) in Participants With Baseline WI-NRS Score ≥4

    The percentage of participants with a baseline WI-NRS ≥ 4 achieving WI-NRS success is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).

    Time frame: Week 4

  5. Achievement of a 4-point Reduction at Week 2 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4

    The percentage of participants with a baseline WI-NRS ≥ 4 achieving WI-NRS success is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).

    Time frame: Week 2

  6. Achievement of a 4-point Reduction at Week 1 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4

    The percentage of participants with a baseline WI-NRS ≥ 4 achieving WI-NRS success is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).

    Time frame: Week 1

  7. Achievement of ≥75% Decrease From Baseline at Week 4 in the Eczema Area and Severity Index (EASI-75)

    The percentage of participants achieving EASI-75 is presented with multiple imputation of missing observations. EASI-75 is a \~75% reduction from the baseline EASI score. EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum = of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.

    Time frame: Week 4

  8. Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4

    The percentage of participants scoring 'clear' or 'almost clear' on viGA-AD is presented with multiple imputation of missing observations. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.

    Time frame: Week 4

  9. Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2

    The percentage of participants scoring 'clear' or 'almost clear' on viGA-AD is presented with multiple imputation of missing observations. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.

    Time frame: Week 2

  10. Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1

    The percentage of participants scoring 'clear' or 'almost clear' on viGA-AD is presented with multiple imputation of missing observations. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.

    Time frame: Week 1

07

Results

Posted Oct 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneRoflumilast Cream 0.15%Vehicle Cream
Started451232
Completed410211
Not completed4121
Withdrew: Withdrawal by subject159
Withdrew: Lost to follow-up106
Withdrew: Adverse event82
Withdrew: Lack of efficacy23
Withdrew: Noncompliance20
Withdrew: Protocol violation20
Withdrew: Physician decision01
Withdrew: Caregiver elected other therapy10
Withdrew: Emergency travel out of country10

Outcome measures

PrimaryAchievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4

The percentage of participants achieving viGA-AD "success" is presented with multiple imputation of missing observations. viGA-AD "success" is defined as a viGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 428.912.0
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.19 · 95% CI 1.962 to 5.183Stratified by pooled study site and vIGA-AD randomization strata
SecondaryAchievement of vIGA-AD Success at Week 4 in Participants With "Moderate" Baseline Scores

The percentage of participants with moderate baseline scores achieving viGA-AD "success" is presented with multiple imputation of missing observations. viGA-AD "success" is defined as a viGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from baseline in participants with a 'moderate' baseline viGA-AD score. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of vIGA-AD Success at Week 4 in Participants With "Moderate" Baseline Scores
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of vIGA-AD Success at Week 4 in Participants With "Moderate" Baseline Scores32.913.1
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.37 · 95% CI 1.996 to 5.687Stratified by pooled study site
SecondaryvIGA-AD Success at Week 2

The percentage of participants achieving viGA-AD "success" is presented with multiple imputation of missing observations. viGA-AD "success" is defined as a viGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.

Time frame:
Week 2
Reported as:
Number · percentage of participants
vIGA-AD Success at Week 2
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
vIGA-AD Success at Week 217.75.3
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.42 · 95% CI 2.281 to 8.658Stratified by pooled study site and vIGA-AD randomization strata
SecondaryvIGA-AD Success at Week 1

The percentage of participants achieving viGA-AD "success" is presented with multiple imputation of missing observations. viGA-AD "success" is defined as a viGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.

Time frame:
Week 1
Reported as:
Number · percentage of participants
vIGA-AD Success at Week 1
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
vIGA-AD Success at Week 15.93.1
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.1156 · Odds ratio (or): 1.99 · 95% CI 0.832 to 4.782Stratified by pooled study site and vIGA-AD randomization strata
SecondaryAchievement of a 4-point Reduction at Week 4 in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) in Participants With Baseline WI-NRS Score ≥4

The percentage of participants with a baseline WI-NRS ≥ 4 achieving WI-NRS success is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of a 4-point Reduction at Week 4 in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) in Participants With Baseline WI-NRS Score ≥4
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of a 4-point Reduction at Week 4 in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) in Participants With Baseline WI-NRS Score ≥430.2 (24.77 to 36.31)12.4 (7.77 to 19.26)
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0014 · Odds ratio (or): 2.71 · 95% CI 1.448 to 5.066Stratified by pooled study site and vIGA-AD randomization strata
SecondaryAchievement of a 4-point Reduction at Week 2 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4

The percentage of participants with a baseline WI-NRS ≥ 4 achieving WI-NRS success is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).

Time frame:
Week 2
Reported as:
Number · percentage of participants
Achievement of a 4-point Reduction at Week 2 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of a 4-point Reduction at Week 2 in the WI-NRS in Participants With Baseline WI-NRS Score ≥422.3 (17.66 to 27.82)6.9 (3.66 to 12.56)
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0015 · Odds ratio (or): 3.55 · 95% CI 1.591 to 7.927Stratified by pooled study site and vIGA-AD randomization strata
SecondaryAchievement of a 4-point Reduction at Week 1 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4

The percentage of participants with a baseline WI-NRS ≥ 4 achieving WI-NRS success is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).

Time frame:
Week 1
Reported as:
Number · percentage of participants
Achievement of a 4-point Reduction at Week 1 in the WI-NRS in Participants With Baseline WI-NRS Score ≥4
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of a 4-point Reduction at Week 1 in the WI-NRS in Participants With Baseline WI-NRS Score ≥411.2 (7.89 to 15.57)1.6 (0.44 to 5.58)
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0020 · Odds ratio (or): 7.84 · 95% CI 1.717 to 35.764Stratified by pooled study site and vIGA-AD randomization strata
SecondaryAchievement of ≥75% Decrease From Baseline at Week 4 in the Eczema Area and Severity Index (EASI-75)

The percentage of participants achieving EASI-75 is presented with multiple imputation of missing observations. EASI-75 is a \~75% reduction from the baseline EASI score. EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum = of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of ≥75% Decrease From Baseline at Week 4 in the Eczema Area and Severity Index (EASI-75)
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of ≥75% Decrease From Baseline at Week 4 in the Eczema Area and Severity Index (EASI-75)42.0 (37.45 to 46.72)19.7 (15.04 to 25.44)
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.23 · 95% CI 2.108 to 4.964Stratified by pooled study site and vIGA-AD randomization strata
SecondaryAchievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4

The percentage of participants scoring 'clear' or 'almost clear' on viGA-AD is presented with multiple imputation of missing observations. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 439.016.9
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.39 · 95% CI 2.191 to 5.240Stratified by pooled study site and vIGA-AD randomization strata
SecondaryAchievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2

The percentage of participants scoring 'clear' or 'almost clear' on viGA-AD is presented with multiple imputation of missing observations. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 227.610.7
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.50 · 95% CI 2.097 to 5.854Stratified by pooled study site and vIGA-AD randomization strata
SecondaryAchievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1

The percentage of participants scoring 'clear' or 'almost clear' on viGA-AD is presented with multiple imputation of missing observations. The viGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.

Time frame:
Week 1
Reported as:
Number · percentage of participants
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1
percentage of participantsRoflumilast Cream 0.15%Vehicle Cream
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 114.26.2
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0050 · Odds ratio (or): 2.56 · 95% CI 1.312 to 4.993Stratified by pooled study site and vIGA-AD randomization strata

Adverse events

Collected over Up to ~29 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Cream 0.15%0/452 (0%)4/452 (0.9%)0/452 (0%)
Vehicle Cream0/232 (0%)0/232 (0%)0/232 (0%)
Most frequent serious events
Most frequent serious events
EventRoflumilast Cream 0.15%Vehicle Cream
Nerve compressionInjury, poisoning and procedural complications1/4520/232
Staphylococcal scalded skin syndromeInfections and infestations1/4520/232
General physical health deteriorationGeneral disorders1/4520/232
Dermatitis atopicSkin and subcutaneous tissue disorders1/4520/232

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast Cream 0.15%Vehicle CreamTotal
Mean27.7 ± 19.6026.2 ± 18.9427.2 ± 19.38
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast Cream 0.15%Vehicle CreamTotal
Female252143395
Male19989288
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roflumilast Cream 0.15%Vehicle CreamTotal
Hispanic or Latino511667
Not Hispanic or Latino397213610
Unknown or Not Reported336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roflumilast Cream 0.15%Vehicle CreamTotal
White268138406
Black or African-American9650146
Asian513081
American-Indian or Alaska Native516
Native Hawaiian or Other Pacific Islander000
Multiple12820
Other19524
Randomization validated Investigator Global Assessment for Atopic Dermatitis (vIGA) Baseline Score
Randomization validated Investigator Global Assessment for Atopic Dermatitis (vIGA) Baseline Score(Participants)Roflumilast Cream 0.15%Vehicle CreamTotal
Mild10953162
Moderate342179521
Investigator-Verified vIGA Baseline Score
Investigator-Verified vIGA Baseline Score(Participants)Roflumilast Cream 0.15%Vehicle CreamTotal
Mild10853161
Moderate343179522
WI-NRS Baseline Score ≥4
WI-NRS Baseline Score ≥4(Participants)Roflumilast Cream 0.15%Vehicle CreamTotal
≥4359181540
≤39251143
Baseline Eczema Area and Severity Index (EASI) Score
Baseline Eczema Area and Severity Index (EASI) Score(units on a scale)Roflumilast Cream 0.15%Vehicle CreamTotal
Median8.50 (6.2 to 12.3)8.4 (6.45 to 12.00)8.50 (6.40 to 12.20)
08

Study locations

53 sites
  • Arcutis Clinical Site 31
    Birmingham, Alabama 35244, United States
  • Arcutis Clinical Site 51
    Fort Smith, Arkansas 72916, United States
  • Arcutis Clinical Site 46
    Inglewood, California 90301, United States
  • Arcutis Clinical Site 19
    San Diego, California 92123, United States
  • Arcutis Clinical Site 36
    San Diego, California 92123, United States
  • Arcutis Clinical Site 13
    Santa Monica, California 90404, United States
  • Arcutis Clinical Site 54
    Centennial, Colorado 80112, United States
  • Arcutis Clinical Site 55
    Boca Raton, Florida 33486, United States
  • Arcutis Clinical Site 30
    Coral Gables, Florida 33146, United States
  • Arcutis Clinical Site 37
    Delray Beach, Florida 33484, United States
  • Arcutis Clinical Site 58
    Miami, Florida 33137, United States
  • Arcutis Clinical Site 41
    Miami, Florida 33144, United States
  • Arcutis Clinical Site 11
    Sanford, Florida 32771, United States
  • Arcutis Clinical Site 57
    West Palm Beach, Florida 33406, United States
  • Arcutis Clinical Site 62
    Boise, Idaho 83706, United States
  • Clinical Site 04
    Plainfield, Indiana 46168, United States
  • Arcutis Clinical Site 43
    Louisville, Kentucky 40241, United States
  • Arcutis Clinical Site 63
    Baton Rouge, Louisiana 70808, United States
  • Arcutis Clinical Site 42
    Lake Charles, Louisiana 70605, United States
  • Arcutis Clinical Site 38
    Mandeville, Louisiana 70448, United States
  • Arcutis Clinical Site 06
    Metairie, Louisiana 70006, United States
  • Arcutis Clinical Site 34
    Rockville, Maryland 20850, United States
  • Arcutis Clinical Site 29
    Clinton Township, Michigan 48038, United States
  • Arcutis Clinical Site 21
    Fort Gratiot, Michigan 48059, United States
  • Arcutis Clinical Site 61
    Troy, Michigan 48084, United States
  • Arcutis Clinical Site 245
    Saint Joseph, Missouri 64506, United States
  • Arcutis Clinical Site 53
    New York, New York 11415, United States
  • Arcutis Clinical Site 39
    Rochester, New York 14623, United States
  • Arcutis Clinical Site 33
    Stony Brook, New York 11790, United States
  • Arcutis Clinical Site 01
    High Point, North Carolina 27262, United States
  • Arcutis Clinical Site 24
    Hershey, Pennsylvania 17033, United States
  • Arcutis Clinical Site 07
    Pittsburgh, Pennsylvania 15213, United States
  • Arcutis Clinical Site 35
    Charleston, South Carolina 29407, United States
  • Arcutis Clinical Site 18
    Charleston, South Carolina 29425, United States
  • Arcutis Clinical Site 15
    North Charleston, South Carolina 29420, United States
  • Clinical Site 05
    Austin, Texas 78759, United States
  • Arcutis Clinical Site 03
    College Station, Texas 77845, United States
  • Arcutis Clinical Site 59
    Frisco, Texas 75034, United States
  • Arcutis Clinical Site 250
    Grapevine, Texas 76051, United States
  • Arcutis Clinical Site 52
    Pflugerville, Texas 78660, United States
  • Arcutis Clinical Site 02
    San Antonio, Texas 78213, United States
  • Arcutis Clinical Site 32
    Orem, Utah 84058, United States
  • Arcutis Clinical Site 22
    Burke, Virginia 22015, United States
  • Arcutis Clinical Site 17
    Norfolk, Virginia 23502, United States
  • Arcutis Clinical Site 12
    Calgary, Alberta T2G 1B1, Canada
  • Arcutis Clinical Site 09
    Surrey, British Columbia V3R 6A7, Canada
  • Arcutis Clinical Site 26
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Arcutis Clinical Site 20
    Ajax, Ontario L1S 7K8, Canada
  • Arcutis Clinical Site 23
    London, Ontario N6H 5L5, Canada
  • Arcutis Clinical Site 25
    Toronto, Ontario M4W 2N4, Canada
  • Arcutis Clinical Site 16
    Waterloo, Ontario N2J 1C4, Canada
  • Arcutis Clinical Site 08
    Drummondville, Quebec J2B 5L4, Canada
  • Arcutis Clinical Site 27
    Québec, Quebec H3Z 2S6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2022, 19 months.

Results were first posted in Oct 2024, 2 years after primary completion. A results delay was requested in Sep 2023.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 19 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Feb 26, 2021
StartActual
Feb 24, 2021
Primary completionActual
Sep 29, 2022
CompletionActual
Sep 29, 2022
Results delay requested
Sep 12, 2023
Results first posted
Oct 4, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04773600
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Feb 24, 2021
Primary completion
Sep 29, 2022
Completion
Sep 29, 2022
Results posted
Oct 4, 2024
Last update
Oct 4, 2024

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion